How Many Uniqure NV (NASDAQ:QURE)’s Analysts Are Bearish?

August 30, 2017 - By Linda Rogers

 How Many Uniqure NV (NASDAQ:QURE)'s Analysts Are Bearish?

Uniqure NV (NASDAQ:QURE) Ratings Coverage

Among 12 analysts covering uniQure N.V. (NASDAQ:QURE), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. uniQure N.V. had 25 analyst reports since August 7, 2015 according to SRatingsIntel. WallachBeth Capital maintained Uniqure NV (NASDAQ:QURE) on Tuesday, December 1 with “Buy” rating. The stock has “Buy” rating by Zacks on Tuesday, September 1. The company was maintained on Monday, September 21 by Oppenheimer. The firm earned “Buy” rating on Monday, September 21 by Roth Capital. As per Monday, November 30, the company rating was reinitiated by Roth Capital. On Friday, August 28 the stock rating was maintained by WallachBeth Capital with “Buy”. The stock of Uniqure NV (NASDAQ:QURE) has “Buy” rating given on Monday, November 30 by TH Capital. As per Wednesday, June 15, the company rating was maintained by WallachBeth Capital. On Monday, September 21 the stock rating was maintained by Piper Jaffray with “Buy”. The stock has “Buy” rating by Chardan Capital Markets on Thursday, October 1. Below is a list of Uniqure NV (NASDAQ:QURE) latest ratings and price target changes.

21/08/2017 Broker: Oppenheimer Rating: Buy New Target: $17.0 Maintain
18/07/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $12.5000 Maintain
12/07/2017 Broker: Cowen & Co Rating: Buy Maintain
28/06/2017 Broker: Oppenheimer Rating: Buy New Target: $17.0000 Maintain

About 39,836 shares traded. Uniqure NV (NASDAQ:QURE) has declined 52.65% since August 30, 2016 and is downtrending. It has underperformed by 69.35% the S&P500.

Uniqure NV is a gene therapy company based in the Netherlands. The company has market cap of $205.03 million. The Firm is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. It currently has negative earnings. The Firm advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

More notable recent Uniqure NV (NASDAQ:QURE) news were published by: Globenewswire.com which released: “uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera …” on April 20, 2017, also Globenewswire.com with their article: “uniQure Announces Company Participation at Citi Healthcare Conference” published on August 24, 2017, Seekingalpha.com published: “uniQure: A Busted Biotech IPO Worth Owning” on August 21, 2017. More interesting news about Uniqure NV (NASDAQ:QURE) were released by: Globenewswire.com and their article: “uniQure Announces Company Presentation at Jefferies Healthcare Conference” published on June 01, 2017 as well as Globenewswire.com‘s news article titled: “uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central …” with publication date: April 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.